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patients have presented with different clinical fea‑
tures, including the nonclassic, subclinical, or as‑
ymptomatic form of the disease.
The pathogenesis of CD is complicated and 
still not fully explained. Besides genetic predis‑
position, the immunological mechanism plays 
the main role in the disease development. Recent 
studies have indicated the direct cytotoxic effect 
of gluten on enterocytes.3 It has been assumed 
that oxidative stress (OS), because of an increase 
in the concentration of reactive oxygen species 
(ROS) and a decrease of antioxidant capacity, is 
INTRODUCTION Celiac disease (CD) is a common 
heritable chronic condition, in which the inges‑
tion of the gluten fraction of wheat or the ade‑
quate proteins from rye and barley causes chron‑
ic inflammation of the small intestine.1 The clin‑
ical presentation of CD is diversified and varies 
with the age of patients, duration of illness, and 
severity of the disease, and extraintestinal man‑
ifestations may be present.2 The classic presenta‑
tion of CD as a predominately pediatric disease 
is characterized by symptoms such as chronic di‑
arrhea, bloating, and growth failure. Adult celiac 
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ABSTRACT
INTRODUCTION Oxidative stress is considered to be one of the mechanisms responsible for gluten 
toxicity, but its role in celiac disease (CD) remains unclear.
OBJECTIVES The aim of the study was to evaluate oxidative imbalance in the pathomechanism of CD 
by determining the concentrations of nitric oxide (NO) and selected antioxidant parameters.
PATIENTS AND METHODS The study involved 197 adult patients: 53 patients with untreated active CD, 
92 celiac patients on gluten ‑free diet (GFD), and 52 controls. The serum levels of antioxidants (uric acid, 
bilirubin, ferritin, albumin), celiac antibodies, NO, glutathione peroxidase 3 (GPx3), and vitamin E were 
measured. A histopathological study of duodenal biopsy was performed.
RESULTS Celiac patients had higher uric acid concentrations than controls (P <0.001). NO levels were 
higher in patients with active CD than in controls (P <0.01) and were correlated with the degree of 
mucosal damage (r2 = 0.04; P = 0.01). Vitamin E levels were decreased in celiac patients (P <0.01), 
and GPx3 activity was reduced in patients with active CD compared with controls (P <0.001).
CONCLUSIONS Oxidative imbalance may be involved in the pathomechanism of CD in adults. GFD only 
partially reduces oxidative stress. Serum NO levels seem to be a marker of the effectiveness of treatment. 
Uric acid may act as an antioxidant in CD.
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so far only in children with classic clinical symp‑
toms of malabsorption syndrome and villous at‑
rophy. Studies on oxidative imbalance in adult ce‑
liac patients with extraintestinal manifestations 
are sparse. To the best of our knowledge, there is 
lack of research on naturally occurring nonenzy‑
matic antioxidants and their role in CD. Therefore, 
we aimed to evaluate the involvement of OS in 
the pathomechanism of CD and to monitor anti‑
oxidant defense in adult celiac patients with ex‑
traintestinal manifestations. For that purpose, 
we examined the levels of fasting plasma nitrate 
as a marker of endogenous NO production and 
monitored individual components of antioxidant 
capacity: GPx3 activity and serum levels of UA, 
ferritin, albumin, bilirubin, and vitamins D and E.
PATIENTS AND METHODS The study included 197 
outpatients and inpatients of the Department of 
Gastroenterology and Hepatology of the Univer‑
sity Hospital in Kraków, Poland (TABLE 1). The first 
group comprised 53 patients with active CD (new‑
ly diagnosed patients as well as patients with CD 
not adhering to GFD, with positive celiac antibody 
titers). The second group included 92 patients 
with treated CD who were on GFD for at least 
2 years (mean [SD] disease duration, 10.4 [8.1] 
years). The third group included 52 patients with 
functional disorders of the gastrointestinal tract, 
without abnormalities on upper gastrointestinal 
endoscopy or on serological and histological ex‑
aminations, who served as controls.
The diagnosis of CD was based on clinical symp‑
toms, positive celiac antibody titers (antitissue 
transglutaminase antibodies [TGA] and/or antien‑
domysial antibodies [EmA]) and the characteris‑
tic histologic features of small intestinal biopsies.
Celiac patients showed nonclassic signs and 
symptoms including extraintestinal manifesta‑
tions such as anemia, iron deficiency without 
gastrointestinal symptoms, chronic abdominal 
pain without typical malabsorption syndrome, 
osteoporosis, osteopenia, as well as asymptom‑
atic disease. Patients with Duhring disease, dia‑
betes, inflammatory bowel disease, current infec‑
tious disease, history of cancer, chronic hepatobi‑
liary disease, chronic renal impairment, alcohol 
abuse, or those receiving chronic nonsteroidal 
anti ‑inflammatory drugs, antioxidant supple‑
ments, oral contraceptives, or immunosuppres‑
sive and immunostimulatory drugs were exclud‑
ed from the study. All patients were nonsmokers.
All participants underwent upper gastrointes‑
tinal endoscopy, and at least 4 duodenal speci‑
mens were obtained for a microscopic examina‑
tion. The degree of intestinal mucosal damage 
was then classified in accordance with the Marsh 
classification.14
On the day of gastroscopy, blood was collect‑
ed by venipuncture to assess serum levels of TGA 
and/or EmA, NO, and antioxidants: vitamins D 
and E, GPx3, UA, albumin, ferritin, and bilirubin. 
The TGA titer was evaluated using a commercial 
enzyme ‑linked immunosorbent assay (ELISA) kit 
one of the processes possibly involved in gliadin 
toxicity.1 Toxic oligopeptides collected in the small 
intestine may lead to toxic effects in genetically 
susceptible individuals.4 However, although OS is 
considered to be one of the mechanisms responsi‑
ble for gluten (gliadin) toxicity, its role in patients 
with CD has not been fully explored. Oxidative 
imbalance induced by gliadin peptides in entero‑
cytes leads to the activation of the transcription 
of proinflammatory cytokines and enzymes such 
as inducible nitric oxide synthase (iNOS), which 
in turn leads to increased production of nitric ox‑
ide (NO) metabolites promoting OS.5 NO takes 
part in the pathogenesis of various inflammatory 
disorders, such as Crohn disease, ulcerative coli‑
tis, and in certain studies, higher NO levels in pa‑
tients with inflammatory bowel disease have been 
shown.6,7 Some studies have reported that reac‑
tive nitrogen species also take part in the patho‑
genesis of CD. The constitutive enzyme iNOS is 
expressed in human enterocytes, with increased 
activity in patients with untreated CD and with 
partial correction in celiac patients on gluten ‑free 
diet (GFD).8,9 It is possible that increased concen‑
tration of fasting plasma NO is a consequence of 
increased iNOS expression in the small intestine. 
Excessive production of NO may lead to increas‑
ing mucosal permeability due to damage to gut 
barrier function.10
In normal conditions, the harmful effects of 
ROS are opposed by the antioxidant defense sys‑
tem consisting of antioxidant enzymes (gluta‑
thione peroxidase [GPx], glutathione reductase 
[GR], superoxide dismutase [SOD], and catalase), 
nonenzymatic antioxidants (such as glutathione 
[GSH], albumin, bilirubin, ceruloplasmin, and uric 
acid [UA]), as well as nutritional antioxidants 
(carotenoids and vitamins A, C, and E).11 The re‑
duced antioxidant defenses may make the in‑
flamed mucosa more sensitive to oxidative tissue 
damage and may disrupt the recovery and integ‑
rity of the mucosa.
Using thiobarbituric acid ‑reactive substances 
as a marker of OS, Odetti et al12 showed that re‑
dox equilibrium is impaired in patients with CD. 
They also observed decreased serum α ‑tocopherol 
levels in a group with silent CD in comparison 
with controls. Earlier studies also showed that 
the activity of SOD is markedly increased in pe‑
diatric patients with CD, while the activity of GPx 
is significantly decreased.13 Interestingly, stud‑
ies concerning the activity of GPx, as most stud‑
ies on the role of OS in CD, have been conducted 
TABLE 1 Characteristics of the study groups
Patient groups Active CD  
(n = 53)
Treated CDa  
(n = 92)
Controls  
(n = 52)
Age, y, mean (SD) 35.9 (11.7) 42.6 (15.1) 39.6 (12.7)
Sex, female/male, n 44/9 77/15 44/8
a Celiac patients on a gluten ‑free diet
Abbreviations: CD, celiac disease
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(P <0.001). The median ferritin level in patients 
with untreated CD was lower than that in treat‑
ed patients (P <0.01).
Serum albumin levels did not differ between 
the celiac groups (mean [SD], 43.0 [4.3] g/l in pa‑
tients with untreated active CD and 43.9 [3.0] g/l 
in patients with treated CD), while they were low‑
er in the control group (P <0.01).
Serum UA concentrations were elevated only 
in celiac patients: in 4 patients (7.5%) with active 
CD and in 4 patients (4.3%) on GFD. UA levels 
were higher in the celiac groups than in controls 
(P <0.001), while bilirubin levels were lower in pa‑
tients with active CD than in controls (P <0.05).
Reduced vitamin D levels were reported in 
37 patients (69.8%) with active CD, in 61 pa‑
tients (66.3%) with treated CD, and in 18 con‑
trols (34.6%). Moderate vitamin D deficiency 
(10–19 ng/ml) was reported in 24 patients (45.3%) 
with untreated CD and 21 patients (22.8%) with 
treated CD; severe deficiency (<10 ng/ml) was re‑
ported in 8 celiac patients (5.5%) and in none of 
the controls. The mean vitamin D level was low‑
er in patients with active CD than in controls or 
treated celiac patients (P <0.001 and P <0.05, re‑
spectively), and was lower in treated celiac pa‑
tients than in controls (P <0.05).
The results of biochemical tests are present‑
ed in TABLE 2.
Serum nitric oxide levels The serum NO level 
was higher in patients with active CD compared 
with controls (mean [SD], 86.4 [61.4] μmol/l vs 
56.8 [37.3] μmol/l, P <0.01). The mean serum NO 
level was lower in patients on GFD than in un‑
treated celiac patients and higher than in controls, 
but the differences were not significant (TABLE 2 
and FIGURE 1).
The degree of intestinal mucosal damage cor‑
related with serum NO levels in celiac patients 
(r2 = 0.04; P = 0.01).
Serum vitamin E levels Serum vitamin E levels 
were lower in untreated celiac patients and in 
treated celiac patients than in controls (mean 
[SD], 41.1 [36.8] μmol/l vs 48.1 [20.8] μmol/l 
and 37.3 [32.1] μmol/l vs 48.1 [20.8] μmol/l, re‑
spectively, P <0.01).
Vitamin E deficiency, defined as the levels low‑
er than 16.2 μmol/l,20 was detected in over 60% of 
celiac patients and in 3.7% of controls. Optimal 
vitamin E levels (>30 μmol/l) required for pro‑
tection against cardiovascular disease and can‑
cer were reported in less than 40% of celiac pa‑
tients and in more than 96% of controls (TABLE 2 
and FIGURE 2).
Serum glutathione peroxidase-3 levels We ob‑
served decreased activity of GPx3 in celiac groups 
compared with controls. The difference was signif‑
icant between active celiac patients and controls 
(mean [SD], 414.7 [107.2] U/l vs 485.4 [89.1] U/l, 
P <0.001). Treated celiac patients showed higher 
activity of GPx3 compared with untreated celiac 
(Aesku Diagnostics GmbH, Wendelsheim, Germa‑
ny). A concentration higher than 15 U/ml was con‑
sidered positive. The EmA titer was assessed with 
the immunofluorescence method. A titer higher 
than 1:10 was regarded as positive.
All study participants provided written in‑
formed consent to participate in the  study. 
The study protocol was approved by the Ethical 
Committee of Jagiellonian University Medical 
College (No. KBET/174/B/2013) and conducted 
according to the Declaration of Helsinki.
Blood sample collection Venous blood samples 
were obtained in the fasting state. The levels of 
albumin, UA, ferritin, bilirubin, and vitamin D 
were evaluated on the same day. For GPx3, NO, 
and vitamin E assays, blood samples were centri‑
fuged at 1000 g for 15 minutes at a temperature 
of 4oC, and the serum was collected and stored 
at a temperature of –80o C until further assay.
Nitric oxide, vitamin E, and glutathione peroxidase-3 
assays The levels of NO and vitamin E were eval‑
uated using commercially available ELISA kits ac‑
cording to the manufacturer’s protocol. NO lev‑
els were determined with the Parameter Total 
Nitric Oxide and Nitrate/Nitrite KGE001 kits 
(R&D Systems, Minneapolis, Minesotta, United 
States) and vitamin E levels—with General Vita‑
min E Elisa Kit E0922Ge (EIAab Science, Wuhan, 
China). A spectrophotometric microplate reader 
(Stat Fax 2100 Awareness Technology Inc., Palm 
City, Florida, United States) was used to deter‑
mine the optical density at 540 nm and 450 nm, 
respectively. The levels of NO and vitamin E were 
calculated from a standard curve. The nitrite con‑
centration in the sample was determined by sub‑
tracting the endogenous nitrite concentration 
from the total nitrite concentration. The plas‑
ma GPx3 level was evaluated with hydrogen per‑
oxide as the substrate, as described previously.15
Statistical analysis For all parameters, descrip‑
tive statistics were calculated. The normality of 
the distribution of parameters was checked by 
the Kolmogorov–Smirnov test. Comparisons be‑
tween the patient groups were performed using 
either the analysis of variance with the Tukey post 
hoc test for parameters with normal distribution 
and homogenous variances or the Kruskal–Wal‑
lis test with the Dunn post hoc test for all oth‑
er parameters. Differences with a P value of less 
than 0.05 were considered significant. Statisti‑
cal calculations were done using the commercial‑
ly available packages STATISTICA PL v.10 (Stat‑
Soft, Tulsa, Oklahoma, United States) and Graph‑
Pad Prism v.3.02 (GraphPad Software, San Diego, 
California, United States), while the correlation 
weights were calculated using the software deliv‑
ered by MP System Sp. z o.o. (Chrzanów, Poland).
RESULTS Blood tests in controls and celiac pa-
tients The mean ferritin level was lower in pa‑
tients with untreated active CD than in controls 
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FIGURE 1 Serum 
concentrations of nitric 
oxide (NO) in controls, 
patients on gluten ‑free 
diet (treated CD), and 
patients with the active 
form of celiac disease 
a P <0.01 (compared 
with the control group)
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TABLE 2 Results of blood tests in the study groups (only the tests with statistically significant results are presented)
Variable Controls (n = 52) Celiac patients (n = 145)
Treated CDa (n = 92) Active CD (n = 53)
Mean (SD) Median Mean (SD) Median Mean (SD) Median
Albumin, g/l 42.0 (3.8) 41.0 43.9 (3.0)c 44.0 43.0 (4.3) 43.0
Bilirubin, µmol/l 10.0 (3.8) 9.4 9.1 (4.4) 8.2 8.5 (5.3)e 7.7
Ferritin, µg/l 53.9 (24.5) 53.0 59.5 (81.9) 35.0 52.3 (163.2) 22.0d,f
GPx3, U/l 485.4 (89.1) 494.2 453.8 (90.4) 460.1 414.7 (107)d 403.2
NO, µmol/l 56.8 (37.3) 45.3 69.7 (41.8) 60.2 86.4 (61.4)c 75.8
Uric acid, µmol/l 190.1 (41.8) 189.0 259.4 (49.6)d 252.0 261.3 (55.2)d 242.0
Total vitamin D, ng/ml 28.1 (5.5) 29.2 24.4 (10.8)e 23.5 20.8 (10.3)b,d 18.8
Vitamin E, µmol/l 48.1 (20.8) 49.9 37.3 (32.1)c 28.9 41.1 (36.8)c 30.3
a Celiac patients on a gluten ‑free diet;   b P <0.05 vs treated CD;   c P <0.01 vs controls;   d P <0.001 vs controls;    
e P <0.05 vs controls;   f P <0.01 vs treated CD
Abbreviations: GPx3, glutathione peroxidase 3; NO, nitric oxide; others, see TABLE 1
FIGURE 2 Serum 
concentrations of 
vitamin E in controls, 
patients on gluten ‑free 
diet (treated CD), and 
patients with the active 
form of celiac disease   
a P <0.01 (compared 
with the control group)
Active CDControl Treated CD
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patients, but the difference was not significant 
(TABLE 2 and FIGURE 3).
Serum levels of celiac antibodies and the degree of in-
testinal mucosal damage The serum levels of celiac 
antibodies were negative in controls. Significantly 
higher levels were observed in untreated celiac pa‑
tients. In treated celiac patients, the levels of an‑
tibodies were significantly lower than in untreat‑
ed celiac patients. The degree of intestinal dam‑
age was the lowest in controls, while it was high‑
er in patients with treated CD and the highest in 
patients with untreated active CD. The differenc‑
es between the groups were significant (TABLE 3).
DISCUSSION The pathogenesis of CD has not 
been fully explained. Because of an increase of 
ROS and the reduced antioxidant protection, 
inflammation and OS seem to participate in 
the pathomechanisms of the disease. Most studies 
concerning the pathomechanism of CD involved 
children with classic clinical symptoms of mal‑
absorption syndrome. However, malabsorption 
alone does not explain the pathophysiology and 
clinical course of numerous extraintestinal mani‑
festations and nonclassic symptoms that predom‑
inate in adult patients with CD. Other possible 
mechanisms include gluten toxicity with oxida‑
tive imbalance and autoimmunity.
To the best of our knowledge, our study is 
the first to have analyzed the serum levels of 
the parameters of oxidative imbalance in adult ce‑
liac patients with extraintestinal manifestations.
NO is produced by NO synthase, an enzyme 
found in a number of cell types. NO has differ‑
ent functions in the gastrointestinal tract, both 
physiological and pathological, and NO synthase 
has 2 forms: constitutive and inducible.16 The lat‑
ter produces NO in response to pathological im‑
pulses such as inflammatory process.17 Some au‑
thors noted increased levels of NO in the serum 
FIGURE 3 Serum 
concentrations of 
glutathione peroxidase 
(GPx3) in controls, 
patients on gluten ‑free 
diet, and patients with 
the active form of celiac 
disease 
a P <0.01 (compared 
with the control group)
Active CDControl Treated CD
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TABLE 3 Clinical characteristics of the study groups: serum levels of celiac 
antibodies and the degree of intestinal mucosal damage
Controls
(n = 52)
Treated CDa
(n = 92)
Active CD
(n = 53)
Antibody titerb
0 52 (100) 89 (96.7) 2 (3.8)
1 0 3 (3.3) 14 (26.4)
2 0 0 18 (34)
3 0 0 19 (35.8)
Mean (SD) 0 0.03 (0.2) 2.02 (0.9)d,e
Median 0 0 2
Degree of intestinal mucosal 
damagec
Normal mucosa 0 51 (96) 31 (33.7) 3 (5.7)
Marsh 1 1 1 (3.8) 31 (33.7) 11 (20.8)
Marsh 2 2 0 0 0
Marsh 3a 3 0 14 (15.2) 11 (20.8)
Marsh 3b 4 0 14 (15.2) 15 (28.3)
Marsh 3c 5 0 2 (2.2) 13 (24.5)
Mean (SD) 0.1 (0.2) 1.5 (1.6) 3.2 (1.7)
Median 0.0 1.0c 4.0d,e
Data are presented as number (percentage) of patients unless indicated otherwise.
a Celiac patients on a gluten ‑free diet
b Antibody titer: 0, negative; 1, normal (TGA <3 × ULN; EmA [+]); 2, high (3 × ULN 
< TGA <10×ULN; EmA [++]); 3, very high (TGA >10 × ULN; EmA [+++])
c The degree of intestinal mucosa damage was classified in accordance with Marsh 
parameters, and each stage was given a score from 0 (normal mucosa) to 5 (total 
villous atrophy); data are presented as number (percentage) of patients.
d P <0.001 vs controls
e P <0.001 vs treated CD
Abbreviations: EmA, antiendomysial antibodies, TGA, antitissue transglutaminase 
antibodies; ULN, upper limit of normal; others, see TABLE 1
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a reduction of GSH levels and decreased GPx and 
GR activity in the peripheral blood of celiac chil‑
dren. In subsequent papers, the same authors 
reported that GPx activity in the small intestine 
was also significantly lower in children with un‑
treated and silent CD than in controls, and they 
showed a positive correlation between GPx ac‑
tivity and both GR and GSH concentrations.13,27
To the best of our knowledge, no previous re‑
search has investigated serum GPx3 levels in adult 
celiac patients. In agreement with the above data, 
our results demonstrated a decreased activity 
of this antioxidant enzyme in the celiac group 
when compared with controls. A significant de‑
crease in GPx3 expression was observed in pa‑
tients with the active form of the disease, which 
means that antioxidant capacity in such patients 
may be reduced. In patients on GFD, the mean ac‑
tivity of GPx3 was slightly increased compared 
with the untreated group, but was lower than in 
controls. The pattern of the observed GPx3 ac‑
tivity in serum seems to be very similar to that 
reported by other authors in intestinal mucosa, 
suggesting that these changes may be system‑
ic. The activity of GPx depends on the availabili‑
ty of GSH and selenium, the depletion of which 
was reported in celiac patients.13,26,27 It appears 
that a reduction in GSH and selenium levels is 
followed by a decrease in GPx activity.
Dietary antioxidants such as vitamin E help 
maintain oxidative balance in a way similar to that 
of other antioxidants. Vitamin E ensures stabili‑
ty of biological membranes, thus protecting from 
harmful cellular effects of ROS, including the del‑
eterious effects of lipid peroxidation.28 Numer‑
ous disorders are related to changes in vitamin E 
levels, but it is unclear whether this is the result 
or the cause of the disease. There have been nu‑
merous reports on the insufficiency of fat ‑soluble 
vitamins in adult subjects with gluten enterop‑
athy.29,30 The plasma or serum concentrations of 
α ‑tocopherol exceeding 16.2 μmol/l are consid‑
ered as sufficient; the levels ranging from 11.6 to 
16.2 indicate low vitamin E levels, and the levels 
of less than 11.6 μmol/l suggest a deficiency. Re‑
cently, it has been proposed that the adequate 
plasma concentration of α ‑tocopherol to prevent 
neoplasm and cardiovascular disorders is more 
than 30 μmol/l.31 In contrast to Hozyasz et al,32 
who reported that in untreated patients the lev‑
els of plasma tocopherol were significantly lower 
compared with those on GFD,32 we showed a sig‑
nificantly decreased serum concentrations of vi‑
tamin E in both celiac groups regardless of com‑
pliance with diet. Noteworthy, the GFD did not 
increase the level of this vitamin. Our observa‑
tions may indicate that oxidative imbalance per‑
sists despite the exclusion of gluten and suggests 
the need for additional supplementation of di‑
etary antioxidants.
We explored, for the first time, the serum lev‑
els of UA as a nonenzymatic plasma antioxidant 
in adult patients with CD. Hyperuricemia is in‑
cluded in metabolic syndrome, and numerous 
and urine of children with CD, with a positive cor‑
relation between the concentration of NO and 
increased concentration of iNOS in the small in‑
testine.10,18‑20 Murray et al17 showed higher plas‑
ma NO concentrations in adult patients with CD 
than in treated patients with CD on GFD and 
those with other upper gastrointestinal disor‑
ders. Ertekin et al19 reported that serum NO lev‑
els decreased after a 1 ‑year GFD in children with 
CD, and there was a significant correlation be‑
tween the degree of intestinal mucosal damage 
and serum NO levels. Higher production of NO 
metabolites, and, in consequence, nitrosative 
stress, promote the impairment of tight junc‑
tions in the small intestine of CD patients, per‑
haps by downregulating the expression of zonu‑
la occludens ‑1.21 These observations are in line 
with the results of our study. We also reported 
a significant correlation between the degree of 
intestinal mucosal damage and the serum NO 
level. Spencer et al22 showed that plasma NO lev‑
els decreased just after the introduction of GFD 
in adults with CD and correlated with intestinal 
changes at diagnosis but not after 6 months of 
treatment with GFD. All these results may imply 
that oxidative injury induced by NO does not de‑
pend on the clinical form but is associated with 
histologic changes. Increased serum levels of NO 
are probably a marker of an ongoing inflamma‑
tion in the small intestine in untreated adult ce‑
liac patients in the same way as in untreated chil‑
dren with CD with classic manifestations. The per‑
sistent significant elevation of serum NO levels 
despite dietary compliance may suggest refrac‑
tory CD and indicate the need for further study, 
including control endoscopy. Hence, it seems to 
be a marker of the effectiveness of treatment.
Elevated OS with increased serum levels of NO 
has also been observed in neurodevelopmental 
conditions such as attention ‑deficit hyperactivi‑
ty disorder and autism spectrum disorders.23 Al‑
though the relationship between these disorders 
and CD is not well established, some authors be‑
lieve that the elevated concentration of NO could 
be useful in identifying the patients who may de‑
rive the greatest therapeutic benefit from GFD.23
It is interesting that patients on GFD in our 
study had also elevated NO serum levels despite 
significant decline in antibody levels. This may in‑
dicate that nitrosative stress in CD patients per‑
sists despite GFD, serological and clinical remis‑
sion, and may be responsible for persistent histo‑
pathological changes. On the other hand, it may 
point to the difficulty in complete elimination 
of all sources of gluten in modern diet; perhaps 
the NO concentration is a more sensitive mark‑
er than TGA in the detection of trace amounts 
of gluten in diet.
The main antioxidant enzymes are SOD, GPx, 
and catalase. GPx is involved in elimination of 
lipid peroxides using GSH as a reducing factor.24 
Ståhlberg et al25 reported a decreased expression 
of GPx in small intestinal mucosa in children with 
total villous atrophy. Stojiljković et al26 showed 
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clinical malabsorption syndrome. Inflammation 
may lead to vitamin D deficiency. It is likely that 
proinflammatory cytokines, such as tumor necro‑
sis factor α, contribute to conversion of 25(OH)D 
to 1,25(OH)2D in the intestine, hence lowering 
the serum concentration of 25(OH)D. In addi‑
tion, 1,25(OH)2D is involved in the inhibition of 
the production of proinflammatory cytokines by 
type‑1 helper T cells, thus reducing inflamma‑
tion.48 This inverse relationship between the ac‑
tivity of CD and serum vitamin D levels was re‑
ported in our current study.
Cholecalciferol (vitamin D3) and its active 
metabolite were found to be membrane antiox‑
idants.48 Their antioxidant properties are rather 
newly recognized and less well studied. Vitamin 
D3 probably contributes to the stability of biologi‑
cal membranes and protects them from the prod‑
ucts of lipid oxidation.48 Vitamin D3 exerts its an‑
tioxidant functions also by affecting the antiox‑
idant enzymes.49 Our study showed a decreased 
serum activity of GPx3 in the study groups with 
reduced serum vitamin D3 levels. Inflammation 
with overexpressed tumor necrosis factor α may 
lead to reducing serum vitamin D3 levels, and on 
the other hand, reduced concentrations of vita‑
min D3 seem to be one of the causes leading to 
the impairment of antioxidant defense. This ob‑
servation indicates that early diagnosis of vita‑
min D3 deficiency is very important in patients 
with CD, particularly in those who do not comply 
with GFD. It seems to be important not only for 
bone metabolism but also for effective treatment 
of intestinal damage by reducing OS. This is es‑
pecially important because, according to a large‑
‑scale Polish study,50 only a very limited percent‑
age of the urban population (9.1%) have adequate 
25(OH)D levels, which is consistent with the Eu‑
ropean and American reports on the vitamin D3 
status. The effect of the vitamin D3 status on OS 
in patients with CD requires further investigation.
A limitation of our study is that we did not as‑
sess the intestinal levels of GPx, NO, and vita‑
min E to compare the pattern of concomitant al‑
terations in intestinal mucosa.
In conclusion, oxidative imbalance appears to 
be one of the main pathomechanisms of CD by 
affecting intestinal damage, the disease course, 
and perhaps extraintestinal disorders. The ob‑
served alterations in the serum concentrations 
of the above parameters of OS and antioxidants 
may suggest that these changes in oxidative im‑
balance are systemic and can contribute to ex‑
traintestinal manifestations. Our results indicate 
that OS persists even in treated patients, although 
to a lesser extent, and that GFD is only partially 
able to improve oxidative imbalance. The serum 
NO level seems to be a marker of the effective‑
ness of treatment, but further studies are neces‑
sary to clarify this issue and to elucidate the po‑
tential role of UA in CD as a marker of OS and 
its potential therapeutic role as an antioxidant. 
Considering that OS is involved in the molecular 
mechanisms of CD, the additional effect of such 
authors have reported a positive correlation be‑
tween the prevalence of metabolic syndrome and 
increased UA concentrations.33,34 In the same way, 
Dao et al34 reported a high rate of metabolic syn‑
drome among patients with gout. To our knowl‑
edge, there have been no studies reporting an in‑
creased incidence of gout in celiac patients.
In our study, we excluded patients with diabe‑
tes and chronic renal impairment, and none of 
the celiac patients had been diagnosed with gout 
or severe dyslipidemia. Hence, it does not seem 
that the observed increase in serum UA concen‑
trations resulted from metabolic disorders or GFD.
UA is considered a marker of oxidative imbal‑
ance as well as an antioxidant with a protective 
feature.35,36 Elevation of the serum UA concentra‑
tion occurs as a physiologic response to increased 
OS.37 It is possible that a high level of UA reflects 
the specific mechanisms for the prevention or cor‑
rection of oxidative damage. Our results may in‑
dicate that higher levels of UA in celiac patients 
compared with controls are a consequence of in‑
creased OS, and that UA may function as an an‑
tioxidant in this case. The role of UA in disorders 
related to OS remains unclear. Glantzounis et al38 
reported that UA acts as an antioxidant in vivo. 
UA also functions as a prooxidant by enhancing 
the levels of free radicals and inducing endotheli‑
al injury, inflammatory process, abnormalities in 
NO concentrations, and atherosclerosis.38 More 
studies are required to explain the role of UA in 
CD and to examine its function as a marker of OS 
as well as an antioxidant.
Similarly to α ‑tocopherol, bilirubin is an an‑
tioxidant that blocks vascular cell adhesion 
molecule ‑1 expression in vitro.39 Significantly low‑
er bilirubin levels were reported in severe asthma 
in an Australian study.40 This may suggest that bil‑
irubin and antioxidant vitamins affected the inad‑
equate control of inflammation in patients with 
asthma. This observation is consistent with our 
result, suggesting an altered concentration of bil‑
irubin as a result of OS. However, the role of bil‑
irubin in oxidative imbalance in CD patients re‑
quires further research.
Ferritin protects against OS by chelation with 
free iron in conditions of excessive OS.41 Data 
on OS and the antioxidant defense system in pa‑
tients with sideropenic anemia are limited and 
debatable.42‑44 Akça et al45 showed increased OS 
in pediatric patients with iron ‑deficiency ane‑
mia and reported its normalization following 
treatment.45 Potaczek et al46 showed that iron 
deficiency is associated with an increased rate of 
venous thromboembolism, and one of the pos‑
tulated mechanism behind that finding was re‑
duced antioxidant defense due to iron deficien‑
cy and reduced GPx activity.47 Iron deficiency in 
celiac patients may have an additional effect on 
the severity of OS; therefore, an adequate treat‑
ment of this deficiency may be important to en‑
hance antioxidant defenses.
In our study, vitamin D deficiency was observed 
in celiac patients despite the absence of classic 
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antioxidants as vitamin E on oxidative imbalance 
may prove to be an effective adjuvant therapy, be‑
sides a rigorous GFD.
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